ClinicalTrials.gg
Not yet recruitingNCT07823088Updated Sep 16, 2026

Open Label Safety Investigation of Solutio™ Tumescent Catheter

An interventional study of Administration of local anesthesia in Venous Insufficiency, sponsored by MedVasc AB. Not yet recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by MedVasc AB · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical investigation is to evaluate safety of the Solutio™ catheter when administering tumescent anesthesia before treatment with endothermal ablation in adults above the age of 18, who suffer from unilateral insufficiency of the great saphenous vein (GSV).

Main question(s) to answer is:

Safety evaluated through reported Adverse Device Effects (ADEs) and Serious Adverse Device Effects (SADEs).

Incidence of Adverse Events (AE), Adverse Device Effects (ADE), Serious Adverse Events (SAE), Serious Adverse Device Effects (SADE), and device deficiency (DD) throughout the investigation.

All investigation participants will:

  • Undergo screening, including medical history, physical examination, and vein mapping with Doppler ultrasound.
  • Have their Great Saphenous Vein (GSV) treated using Seldinger technique under ultrasound guidance.
  • Receive tumescent anesthesia injected from inside the vein into the perivascular tissue at selected sites along the vein, using the investigational Solutio™ catheter under ultrasound guidance.
  • Undergo endothermal ablation, Endovenous Laser Ablation (EVLA), or Radiofrequency Ablation (RFA).
  • Be followed up for 28 days through scheduled phone calls (Day 1, Day 14 ±2) and clinic visits (Day 7 ±1, Day 28 ±2) to assess adverse events, pain, patient comfort, and undergo physical/clinical examinations and ultrasound examinations of the treated area.
02

Conditions studied

  • Venous Insufficiency

Browse trials for

03

In context

Venous Insufficiency

162 studies on the registry are indexed under Venous Insufficiency; 14 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 127 interventional studies indexed under Venous Insufficiency.

Browse Venous Insufficiency studies →

Lead sponsor

This is the only study on the registry with MedVasc AB as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female >18 years old.
  2. Subject diagnosed with venous insufficiency in the Great Saphenous Vein from the groin to the proximal 1/3 of the lower leg and with a Clinical Etiological Anatomical Pathophysiological (CEAP) classification of 2 or higher.
  3. Subject is scheduled for an EVLA or RFA procedure for a unilateral insufficiency of the GSV.
  4. Subject accepts to be treated with endothermal ablation as a standalone method.
  5. Subject accepts to be treated without any sedation.
  6. Subject is willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Considered as being of high risk due to comorbidity in the opinion of the investigator.
  2. Subject with known and confirmed coagulation defects.
  3. Subject on anticoagulant treatment.
  4. Subject who simultaneously needs to be treated with other supplemental techniques such as e.g., foam sclerotherapy, ligation, and phlebectomy.
  5. Subject with GSV insufficiency in the distal 2/3 of the lower leg.
  6. Subject, who demands full sedation, or general anesthesia.
  7. Subject with known allergy to any of the tumescent and/or anesthetizing agents that will be used (per local standard practice) during the endothermal ablation procedure.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Solutio™ catheter used to administrate tumescence during endothermal ablation of varicose veins

    Administration of tumescence from inside the vein to the surrounding tissue, via Solutio™ catheter during endothermal ablation of varicose veins.

    Device: Administration of local anesthesia

Interventions

  • DeviceAdministration of local anesthesia

    The Solutio™ catheter presents a technique that allows for tumescent anesthesia injections to be administered at selected sites along the vein, from inside the vein to the surrounding tissue. The purpose of the Solutio™ catheter is to prevent the pain associated with multiple injections, through sensitive skin layers along the inner side of the leg, administered prior to ablation.

06

What researchers measure

Primary outcomes

  1. Safety related to the procedure using the Solutio™ catheter.

    Safety evaluated by recording the number and type of adverse device effects (ADEs) and serious adverse device effects (SADEs) related to the procedure using the Solutio™ catheter.

    Time frame: 28 days

Secondary outcomes

  1. Patient experience of pain

    The patient will rate their experience of pain at follow up visits at the clinic and via phone contacts. A Visual Analogue Scale (VAS) measures pain intensity. The scale consists of a 100 mm line, with two end points representing 0 = "no pain" and 100 = "worst pain imaginable". The patient will be asked to make a mark across the line according to the maximum experienced pain to indicate their pain at given timepoints. At phone contacts the patient is asked a standard question to rate their pain with a number from 0 to 10, a Numeric Rating Scale (NRS), where 0 = "no pain" and 10 = "worst pain imaginable"

    Time frame: 28 days

  2. Physician feedback

    After the end of the procedure, the physician is asked to provide their feedback, assessment about 10 different aspects during the procedure. They will answer with a 4-grade scale (1 is excellent, 2 is good, 3 is fair, 4 is impossible /inadequate). Acceptable score is ≤3 for each question.

    Time frame: 1 day

  3. Patient experience of pain

    At phone contacts the patient is asked a standardized question to rate their pain with a number from 0 to 10, a Numeric Rating Scale (NRS), where 0 = "no pain" and 10 = "worst pain imaginable".

    Time frame: 28 days

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 46 interventional studies with no phase under Venous Insufficiency, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 16, 2026
StartEst.
Sep 28, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Feb 28, 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07823088
Lead sponsor
MedVasc AB
Responsible party
Sponsor
First posted
Sep 16, 2026
Start date
Sep 28, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Sep 16, 2026

Study contacts

Ingegerd W Dalfelt, SRN, BSc.
Contact
ingegerd.dalfelt@gmail.com
+46708433348
Cathrin Johansson, BSc
Contact
cathrin.johansson@medvasc.se
+46708548834
Michael Akesson, MD
study director · MedVasc AB

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion